MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Huntington’s Disease: Determinants for Cognitive Disease Progression – A Proposed Model

N. Gonçalves, J. Mendes, J. Ferreira, C. Sampaio (Lisbon, Portugal)

Meeting: 2017 International Congress

Abstract Number: 465

Keywords: Cognitive dysfunction

Session Information

Date: Tuesday, June 6, 2017

Session Title: Huntington's Disease

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: To develop a conceptual model to determine the rate of cognition impairment in Huntington’s disease manifest patients and to identify the factors that influence the progression rate.

Background: Huntington’s disease is an inherited autosomal dominant neurodegenerative disease caused by a gene mutation, which results in progressive deterioration of the motor and cognitive abilities. The nature and extend of cognitive impairment is not clearly identified because in-between of the prodromal phase and the late stage there is lack of information on how it progresses. There is evidence that cognition impairment can be affected by functional and motor conditions, CAG repeats, education level and sex.

Methods: A theory-driven longitudinal structural equation model was developed. Cognition was measured by six indicators: Symbol Digit Modality Test, Stroop Word Reading, Stroop Color Naming, Trail Making Test part A and B, Verbal Fluency Test and Strop Interference Test. Longitudinal data from Enroll-HD public dataset (December 2016) was used to validate the model. The full model was estimated in R with package semPLS. The measurement model was validated trough reliability and validity measures.

Results: 134 HD manifest participants were considered with 4 years of follow up, 58% male, mean age 53.5±11.6 yo; 58% have a ISCED level higher than 3. Mean CAG repeats was 43.4±3.6 and motor onset 47.1±10.8 yo. Motor score was 26.9±13.5, TFC score 9.5±2.9 and FAS score 21.1±4.4. The reliability of the model was higher than 0.90 and convergent validity above 0.5 for all the latent variables; the average R2 was 0.79. The rate of cognition decline is low in the first 2 years (1%), increasing to 9% between the third and fourth year. Indicators for attention and integration of information do not have impact on cognition after three years of evaluation. Except for sex, all other variables do not have a significant impact on cognition impairment. The rate of progression in women is higher than the global average between the third and fourth year (20%), and also when compared with men rate of progression.

Conclusions: The conceptual model for cognition impairment was validated and sex was identified as a relevant factor for cognition decline. The characteristics of the manifest population studied may influence the rate of progression and therefore the model should be validated using other HD datasets.

To cite this abstract in AMA style:

N. Gonçalves, J. Mendes, J. Ferreira, C. Sampaio. Huntington’s Disease: Determinants for Cognitive Disease Progression – A Proposed Model [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/huntingtons-disease-determinants-for-cognitive-disease-progression-a-proposed-model/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/huntingtons-disease-determinants-for-cognitive-disease-progression-a-proposed-model/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley